Cassava Sciences (NASDAQ:SAVA) slid 13% in early Monday trading after the company disclosed that the U.S. Food and Drug Administration has asked for more information related to its investigational new drug (IND) filing.

According to the company, the FDA notified Cassava on December 2 that it requires further data to evaluate potential risks to human participants in studies of simufilam, which the biotech is developing as a treatment for epilepsy associated with tuberous sclerosis complex (TSC). The IND application had been submitted to support a planned proof-of-concept clinical trial for this new indication.

Cassava said it expects a formal written communication outlining the specific deficiencies raised by regulators and intends to work with the FDA to address the issues.

Despite the request, the company reiterated that it still aims to begin its proof-of-concept study for simufilam in TSC-related epilepsy during the first half of 2026, suggesting the additional data requirement is not expected to materially alter its development schedule.

Tuberous sclerosis complex is a rare hereditary disorder that leads to benign tumor growth in multiple organs and frequently causes epilepsy and neurological difficulties.

Cassava Sciences stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.